AMENDMENTS TO THE CLAIMS

1. **Cancelled**

2. **Cancelled**

3. **Cancelled**

4. **(Currently Amended)** ~~The~~ An isolated polypeptide ~~of Claim 1~~ having at least 95% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide ~~shown in Figure 48 (SEQ ID NO:48)~~ of SEQ ID NO: 48;

(b) the amino acid sequence of the polypeptide ~~shown in Figure 48 (SEQ ID NO:48)~~ of SEQ ID NO: 48, lacking its associated signal peptide;

(c) the amino acid sequence of the extracellular domain of the polypeptide ~~shown in Figure 48 (SEQ ID NO:48)~~ of SEQ ID NO: 48;

(d) the amino acid sequence of the extracellular domain of the polypeptide ~~shown in Figure 48 (SEQ ID NO:48), lacking~~ of SEQ ID NO: 48, including its associated signal peptide; or

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203018;

wherein said extracellular domain is selected from the group consisting of amino acids 32-49 and amino acids 111-190 of SEQ ID NO: 48; and

wherein said isolated polypeptide is more highly expressed in normal stomach tissue or rectum tumor compared to stomach tumor or normal rectum tissue respectively, or wherein said isolated polypeptide is encoded by a polynucleotide that is more highly expressed in normal stomach tissue or rectum tumor compared to stomach tumor or normal rectum tissue respectively.

5. **(Currently Amended)** The isolated polypeptide of ~~Claim 1~~ Claim 4 having at least 99% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide ~~shown in Figure 48 (SEQ ID NO:48)~~ of SEQ ID NO: 48;

(b) the amino acid sequence of the polypeptide ~~shown in Figure 48 (SEQ ID NO:48)~~ of SEQ ID NO: 48, lacking its associated signal peptide;

(c) the amino acid sequence of the extracellular domain of the polypeptide ~~shown in Figure 48 (SEQ ID NO:48)~~ of SEQ ID NO: 48;

(d) the amino acid sequence of the extracellular domain of the polypeptide ~~shown in Figure 48 (SEQ ID NO:48), lacking~~ of SEQ ID NO: 48, including its associated signal peptide; or

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203018;

wherein said extracellular domain is selected from the group consisting of amino acids 32-49 and amino acids 111-190 of SEQ ID NO: 48; and

wherein said isolated polypeptide is more highly expressed in normal stomach tissue or rectum tumor compared to stomach tumor or normal rectum tissue respectively, or wherein said isolated polypeptide is encoded by a polynucleotide that is more highly expressed in normal stomach tissue or rectum tumor compared to stomach tumor or normal rectum tissue respectively.

6. **(Currently Amended)** An isolated polypeptide comprising:

(a) the amino acid sequence of the polypeptide ~~shown in Figure 48 (SEQ ID NO:48)~~ of SEQ ID NO: 48;

(b) the amino acid sequence of the polypeptide ~~shown in Figure 48 (SEQ ID NO:48)~~ of SEQ ID NO: 48, lacking its associated signal peptide;

(c) the amino acid sequence of the extracellular domain of the polypeptide ~~shown in Figure 48 (SEQ ID NO:48)~~ of SEQ ID NO: 48;

(d) the amino acid sequence of the extracellular domain of the polypeptide ~~shown in Figure 48 (SEQ ID NO:48), lacking~~ of SEQ ID NO: 48, including its associated signal peptide; or

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203018;

wherein said extracellular domain is selected from the group consisting of amino acids 32-49 and amino acids 111-190 of SEQ ID NO: 48.

7. **(Currently Amended)** The isolated polypeptide of Claim 6 comprising the amino acid sequence of the polypeptide ~~shown in Figure 48 (SEQ ID NO:48)~~ of SEQ ID NO: 48.

8. **(Currently Amended)** The isolated polypeptide of Claim 6 comprising the amino acid sequence of the polypeptide ~~shown in Figure 48 (SEQ ID NO:48)~~ of SEQ ID NO: 48, lacking its associated signal peptide, wherein said extracellular domain is selected from the group consisting of amino acids 32-49 and amino acids 111-190 of SEQ ID NO: 48.

9. **(Currently Amended)** The isolated polypeptide of Claim 6 comprising the amino acid sequence of the extracellular domain of the polypeptide ~~shown in Figure 48 (SEQ ID NO:48)~~ of SEQ ID NO: 48, wherein said extracellular domain is selected from the group consisting of amino acids 32-49 and amino acids 111-190 of SEQ ID NO: 48.

10. **(Currently Amended)** The isolated polypeptide of Claim 6 comprising the amino acid sequence of the extracellular domain of the polypeptide ~~shown in Figure 48 (SEQ ID NO:48)~~ of SEQ ID NO: 48, lacking its associated signal peptide, wherein said extracellular domain is selected from the group consisting of amino acids 32-49 and amino acids 111-190 of SEQ ID NO: 48.

11. **(Original)** The isolated polypeptide of Claim 6 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203018.

12. **(Currently Amended)** A chimeric polypeptide comprising a polypeptide according to ~~Claim 1~~ Claim 4 fused to a heterologous polypeptide.

13. **(Currently Amended)** The chimeric polypeptide of Claim 12, wherein said heterologous polypeptide is ~~an epitope~~ a tag polypeptide or an Fc region of an immunoglobulin.

14. **(New)** An isolated polypeptide having at least 95% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of SEQ ID NO: 48;

(b) the amino acid sequence of the polypeptide of SEQ ID NO: 48, lacking its associated signal peptide;

(c) the amino acid sequence of the extracellular domain of the polypeptide of SEQ ID NO: 48;

(d) the amino acid sequence of the extracellular domain of the polypeptide of SEQ ID NO: 74, including its associated signal peptide; or

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203018;

wherein said extracellular domain is selected from the group consisting of amino acids 32-49 and amino acids 111-190 of SEQ ID NO: 48; and

wherein said isolated polypeptide or a fragment thereof can be used to generate an antibody which can be used to specifically detect the polypeptide of SEQ ID NO: 48 in stomach or rectum tissue samples.

15. **(New)** The isolated polypeptide of Claim 14 having at least 99% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of SEQ ID NO: 48;

(b) the amino acid sequence of the polypeptide of SEQ ID NO: 48, lacking its associated signal peptide;

(c) the amino acid sequence of the extracellular domain of the polypeptide of SEQ ID NO: 48;

(d) the amino acid sequence of the extracellular domain of the polypeptide of SEQ ID NO: 74, including its associated signal peptide; or

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203018;

wherein said extracellular domain is selected from the group consisting of amino acids 32-49 and amino acids 111-190 of SEQ ID NO: 48; and

wherein said isolated polypeptide or a fragment thereof can be used to generate an antibody which can be used to specifically detect the polypeptide of SEQ ID NO: 48 in stomach or rectum tissue samples.

16. **(New)** A chimeric polypeptide comprising a polypeptide according to Claim 14 fused to a heterologous polypeptide.

17. **(New)** The chimeric polypeptide of Claim 16, wherein said heterologous polypeptide is a tag polypeptide or an Fc region of an immunoglobulin.

DELETION OF INVENTORS

Please correct the inventorship under 37 CFR §1.48(b) by removing the following inventors from the present application:

Dan L. Eaton, Ellen Filvaroff, Mary E. Gerritsen, and Colin K. Watanabe